Use of IRESSA® in patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) failed to prolong survival and increased bleeding events

From Health Canada:
AstraZeneca Canada Inc., in consultation with Health Canada, would like to inform all patients in the IRESSA Patient Registry (IPR) Program of new information from a clinical trial on the use of IRESSA in patients who have head and neck cancer. It should be noted that head and neck cancer is not an approved use for IRESSA, but patients with this diagnosis may be participating in the IPR Program if benefiting from therapy.
For the Public